CLINICAL_TRIALS trial_result · 2017-03-20

Clinical Trial Update: Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD) [Phase 3]

Phase 3 safety and efficacy study of SHP465 in children and adolescents with ADHD has completed; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Shire | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Status: COMPLETED | Results posted: 2017-03-20